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Summary
 
Asthma
 
 
 
is a chronic disease characterized by increased airway responsiveness and airway inflam-
mation. The functional role of nitric oxide (NO) and the various nitric oxide synthase (NOS)
isoforms in human asthma is controversial. To investigate the role of NO in an established model
of allergic asthma, mice with targeted deletions of the three known isoforms of NOS (NOS1, 2,
and 3) were studied. Although the inducible (NOS2) isoform was significantly upregulated in the
lungs of ovalbumin (OVA)-sensitized and -challenged (OVA/OVA) wild-type (WT) mice and
was undetectable in similarly treated NOS2-deficient mice, airway responsiveness was not signifi-
cantly different between these groups. OVA/OVA endothelial (NOS3)-deficient mice were sig-
nificantly more responsive to methacholine challenge compared with similarly treated NOS1 and
NOS1&3-deficient mice. Airway responsiveness in OVA/OVA neuronal (NOS1)-deficient and
neuronal/endothelial (NOS1&3) double-deficient mice was significantly less than that observed
in similarly treated NOS2 and WT groups. These findings demonstrate an important function for
the nNOS isoform in controlling the inducibility of airway hyperresponsiveness in this model of
allergic asthma.
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A
 
sthma
 
 
 
is an inflammatory disease of the airways char-
acterized by airway obstruction and increased airway
responsiveness (1). Animal models of allergic asthma ex-
hibit many of the features of human asthma, including air-
way hyperresponsiveness, airway inflammation, and in-
creased serum IgE levels (2–7); these models have been
useful in elucidating the pathobiology of the asthmatic re-
sponse. Nitric oxide (NO)
 
1
 
 is a short-lived molecule that
has been shown to have a number of important biological
functions in various diseases including asthma (8–13). Sev-
eral studies have clearly demonstrated the presence of in-
creased NO concentrations in the exhaled air of asthmatics
(12–14) and normalization of expired NO concentrations
after treatment with corticosteroids (15). Despite these ob-
servations, the role of NO in asthma remains controversial.
It has been suggested that NO is a marker of inflammation
(16, 17) and a cytotoxic molecule contributing to epithelial
damage (18). NO has also been reported to be a weak bron-
chodilator (19–21) or to have no effect on airway caliber
(22–24). Nitric oxide is produced by a group of enzymes
commonly referred to as nitric oxide synthases (NOSs). The
enzymes found in endothelial (eNOS, NOS3) and neu-
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; cNOS, con-
stitutive NOS; eNOS, endothelial NOS; EPO, eosinophil peroxidase;
iNOS, inducible NOS; KO, knockout; nNOS, neuronal NOS; NO, ni-
tric oxide; NOS, nitric oxide synthase; R
 
L
 
, pulmonary resistance; SPF,
sterile pathogen-free; WT, wild-type. 
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ronal (nNOS, NOS1) cells are usually constitutively ex-
pressed, whereas the form of NOS expressed in numerous
cell types including macrophages, endothelial cells, epithe-
lial cells, and neutrophils is inducible and termed iNOS
(NOS2) (25–27). Of the three enzyme isoforms identified,
only iNOS has been believed to play an important role in
asthma (18, 28). It has been shown by immunostaining that
iNOS expression is increased in the airways of asthmatics
(18), which suggests that iNOS probably contributes most
to the increase in exhaled NO concentrations observed in
asthma (28). The functional role of nNOS and eNOS in
asthma is uncertain (29–31). To understand the actions of
the individual NOS isoforms, investigators have used sev-
eral NOS inhibitors to try to dissect out the role of consti-
tutive and inducible forms of NOS (32); these studies are
subject to the problems of NOS inhibitor specificity and
concerns about inhibitor uptake, distribution, and metabo-
lism. The availability of mouse strains with targeted dele-
tions of these three NOS isoforms, as either single or dou-
ble deletions, provides an alternative approach to dissect
out the contribution of each NOS isoform in models of
disease (32–34). We previously used this strategy to investi-
gate the role of the nNOS gene in regulating baseline air-
way responsiveness in the mouse (29). Targeted deletion of
the nNOS gene in the mouse was associated with a de-
crease in airway responsiveness and exhaled NO concen-
trations (29). No other known studies have been carried
out to isolate the contribution of the iNOS and eNOS iso-
forms in either naive animals or a model of allergic asthma
in targeted gene knockouts (KOs). Given the significant re-
duction in airway responsiveness in the nNOS KO mouse
and given that several recent genetic studies have reported
evidence of linkage of the diagnosis of asthma (35–37) with
the region harboring the nNOS gene in humans, we exam-
ined the contribution of each NOS isoform to the expres-
sion of various facets of airway inflammation and physiol-
ogy in an established murine model of allergic asthma.
 
Materials and Methods
 
Animals.
 
Neuronal (NOS1-KO), endothelial (NOS3-KO),
and double neuronal and endothelial KO mice (NOS1&3-KO)
and matched wild-type (WT) controls were bred in a sterile patho-
gen-free (SPF) barrier facility. These three gene-targeted mutants
were produced on a mixed SV129/C57BL/6 background (38–40).
The iNOS KO mice (NOS2-KO) were purchased from The Jack-
son Laboratory and were backcrossed for 
 
.
 
10 generations onto a
C57BL6/J (B6) background, the controls for the NOS2 KO mice.
To control for gender-induced differences in airway reactivity, only
male offspring were used for these studies. All mice were 4–5 wk
old at entry into the protocol. Mice were housed in isolation cages
under SPF conditions. Blood from sentinel animals was routinely
tested to ensure their SPF status. All mice were acclimatized for
7–10 d after arrival and were studied at 7–8 wk of age.
In one set of experiments the whole body plethysmographic
method (Buxco
 
®
 
) was used to assess airway responsiveness in a
different cohort of iNOS KO mice (41). These iNOS KO mice
were provided by Drs. J.S. Mudgett (Merck Research Labs.,
Rahway, NJ), J.D. MacMicking, and C. Nathan (both from
 
Cornell University Medical College, New York, NY) and had
been backcrossed into a B6 background. Sex- and age-matched
B6 mice were used as controls for the NOS2 group.
 
Experimental Design.
 
The gene targeted mutants type (NOS1-
KO, NOS3-KO, NOS2-KO, and NOS1&3-KO) and matched
WT control mice (on the appropriate genetic background) were
all sensitized to chicken OVA (Grade III; Sigma Chemical Co.).
Sensitized mice were then randomized to repeated exposure ei-
ther to an aerosol generated from an OVA solution or to PBS.
 
Sensitization and Challenge Protocol.
 
Two protocols were used
in this study. In the first set of experiments, all mice were immu-
nized on day 0 via an intraperitoneal injection with 10 
 
m
 
g chicken
OVA, mixed with 1 mg Al(OH)
 
3
 
 (alum; J.T. Baker Chemical) in
0.2 ml of PBS as previously described (7). A booster injection was
given on day 7 using the identical reagents. Starting 7 d later,
mice were exposed either to aerosolized OVA (6% OVA) dis-
solved in PBS (pH 
 
5 
 
7.4) or to PBS alone for 25 min per day for
7 d consecutively. All mice were studied 24 h after the last aero-
sol (day 21). For the aerosol exposures mice were placed in a
plastic chamber (23 
 
3
 
 23 
 
3
 
 11 cm), and the OVA or PBS solu-
tion was delivered via an ultrasonic nebulizer (model 5000; De-
Vilbiss) attached to a port in the mouse chamber.
For mice studied using the whole body plethysmographic
method of assessing airway responsiveness (Buxco
 
®
 
), mice were
immunized on day 0 via an intraperitoneal injection with 20 
 
m
 
g
chicken OVA mixed with 2 mg Al(OH)
 
3
 
. A booster injection was
given on day 7 using 10 
 
m
 
g chicken OVA mixed with 1 mg
Al(OH)
 
3
 
. All mice were exposed either to aerosolized OVA (3%
OVA) or PBS for 10 min on days 14, 15, and 16, studied on day 17
(airway responsiveness measured by whole body plethysmography),
and killed on day 18 (for bronchoalveolar lavage [BAL] and har-
vesting of tissues).
 
Determination of Anti-OVA IgE Antibody Serum Titers.
 
OVA-
specific IgE levels were measured by capture ELISA as previously
described (42). ELISA plates were coated with a purified anti–
mouse IgE mAb (PharMingen) at a concentration of 2 
 
m
 
g/ml and
blocked with PBS/10% FCS. Serum samples were diluted in
PBS/10% FCS and incubated in the wells for 2 h. After washing
with 0.05% PBS/Tween 20, biotinylated OVA (10 
 
m
 
g/ml) was
added to the wells and incubated for 1 h. The plates were washed
with PBS/Tween 20 followed by the addition of avidin alkaline
phosphatase (Sigma Chemical Co.) for 1 h. The plates were then
washed with PBS/Tween 20 and distilled water, before the addi-
tion of the phosphatase substrate. The plates were allowed to de-
velop for 30 min and read in an ELISA plate reader at 405 nm.
 
Assessment of In Vitro Pulmonary NOS Activity.
 
Pulmonary NOS
activity was measured using a modification of an in vitro
[
 
3
 
H]
 
l
 
-arginine to [
 
3
 
H]
 
l
 
-citrulline conversion assay that has been
described previously (43). Mouse lungs were kept frozen (
 
2
 
80
 
8
 
C)
until the day of assay when they were homogenized in 10 vol of
50 mM potassium phosphate (pH 7.4). A 50-
 
m
 
l aliquot was incu-
bated at 37
 
8
 
C for 15 min in 100 
 
m
 
l of incubation buffer (50 mM
potassium phosphate, 60 mM 
 
l
 
-valine, 1 mg/ml BSA, 1 mM
NADPH, 10 
 
m
 
M FAD, 10 
 
m
 
M tetrahydrobiopterin, 30 
 
m
 
M
[2,3-
 
3
 
H]
 
l
 
-arginine [200 counts/min/pmol], and 1.2 mM MgCl
 
2
 
;
pH 7.4). In the quantification of calcium-dependent NOS activ-
ity, indicating both constitutive calcium-dependent forms (i.e.,
nNOS and eNOS) and therefore termed cNOS, calmodulin (100
nM) and CaCl
 
2
 
 (1 mM) were added to the incubation buffer. In
contrast, EDTA (1.2 mM) and ethylene glycol-bis(b-aminoethyl
ether) N,N,N
 
9
 
,N
 
9
 
-tetraacetic acid (EGTA; 1 mM) were added to
the incubation buffer when measuring calcium-independent
(iNOS) NOS activity. A third incubation condition of EDTA/ 
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EGTA and 
 
l
 
-
 
N
 
G
 
-nitro-arginine methyl ester (
 
l
 
-NAME; 1 mM)
was used to account for nonspecific radiation and nonspecific
metabolism (i.e., non-NOS-mediated conversion) of [
 
3
 
H]
 
l
 
-argi-
nine. The reaction was terminated by the addition of 500 
 
m
 
l of
ice-cold stop buffer (4
 
8
 
C; 100 mM Hepes and 12 mM EDTA,
pH 5.5) and 2 ml of 50% Dowex 50W (200–400, 8% cross-
linked, Na
 
1
 
 form, pH 7.0) in water in order to remove any ex-
cess [
 
3
 
H]
 
l
 
-arginine. Samples were centrifuged for 20 min at 600 
 
g
 
and 0.5 ml of the supernatant was added to 4.5 ml of scintillation
fluid; radioactivity was measured by liquid scintillation counting
(Beckman Scientific Instruments). cNOS activity was calculated
as the difference between the calcium–calmodulin sample (total
NOS activity) and the EDTA–EGTA sample. iNOS activity was
defined as the 
 
l
 
-NAME–inhibitable proportion of the activity
found in the samples containing EDTA/EGTA.
 
Measurement of Airway Responsiveness.
 
Airway responsiveness was
measured by two different methods in our study. In the first set of
experiments
 
 
 
airway responsiveness was measured in anesthetized
mice using a sealed constant mass plethysmograph as previously
described (7, 29, 44–46). In brief, dose–response curves to metha-
choline (Sigma Chemical Co.) were obtained 24 h after the last
aerosol exposure of either OVA or PBS by administering sequen-
tially increasing doses of methacholine intravenously (33–3,300
 
m
 
g/kg) in a 20–35-
 
m
 
l volume. From the relationship between
the administered dose and pulmonary resistance (R
 
L
 
), the effec-
tive dose required to increase R
 
L
 
 to 200% of control values
(ED
 
200
 
R
 
L
 
), was determined by log-linear interpolation. ED
 
200
 
R
 
L
 
is an index of airway responsiveness.
In a second set of experiments, an alternative method of mea-
suring airway responsiveness was adopted.
 
 
 
This was done to con-
firm the results of a specific experiment and to see if the results
could be reproduced in unanesthetized mice. The whole body
plethysmograph system was therefore used to measure airway re-
sponsiveness in these experiments (47, 48). The day after the last
allergen challenge, each mouse was placed in a chamber and box
pressure/time wave form was analyzed to yield the indicator of
airflow obstruction, Penh. PBS or methacholine was given by
aerosol in increasing concentrations through an inlet of the
chamber for 1 min and readings were taken for 9 min at each
dose step. Penh values averaged for 5 min after each nebulization
were evaluated.
 
Bronchoalveolar Lavage.
 
After the termination of the experi-
ments, BAL was performed on mice in each of the four treatment
groups for NOS gene KO and WT strains. 2 ml of PBS with 0.6
mM EDTA was instilled into the lungs and retrieved using gentle
suction. The lavage was centrifuged at 2,000 
 
g
 
 for 10 min, the su-
pernatant was separated from the cell pellet, and aliquots were
frozen at 
 
2
 
70
 
8
 
C for cytokine analysis. The cell pellets were re-
suspended in Hank’s balanced salt medium (JRH Biosciences)
and slides were prepared by spinning samples at 800 rpm for 10
min (Cytospin 2; Shandon). Total cell counts were made in a
hemocytometer and differentials were prepared by cytospin and
stained with Wright-Giemsa stain. The investigator counting the
cells was blinded to the treatment groups.
 
Measurement of Eosinophil Peroxidase and Protein in Bronchoal-
veolar Lavage Fluid.
 
Eosinophil peroxidase (EPO) levels in the
lavage were measured colorimetrically as previously described
(2, 49). 100 
 
m
 
l of sample or standard, porcine EPO (ExOxEmis
Corp.) were pipetted, in duplicate, into the wells of a 96-well
plate (Cell Wells™; Corning) followed by 100 
 
m
 
l of assay reaction
mixture containing 0.05 M Tris buffer [Tris(hydroxymethyl)amino-
methane; Trizma
 
®
 
; Sigma Chemical Co.], 0.1 
 
m
 
l 30% H
 
2
 
O
 
2
 
(Fisher Scientific Co.), 0.015% Triton X-100 (Sigma Chemical
 
Co.), pH
 
 
 
8.0, and 0.05 M ortho-phenylenediamine (Sigma
Chemical Co.). The plate was incubated in the dark for 30 min
and the reaction was terminated with 50 
 
m
 
l of 4 M H
 
2
 
SO
 
4
 
 per
well and then read on a plate reader (Spectramax Model 340; Mo-
lecular Devices Corp.) at 490 nm. A BCA protein assay (Pierce
Scientific) was used to quantitate lavage protein. All regression
analysis was performed using the Softmax Pro software (Spectra-
max Plate Reader Model 340; Molecular Devices Corp.).
 
Histological Evaluation.
 
Mice were removed from the plethys-
mograph while under surgical anesthesia and killed by cervical
dislocation. Blood was collected by cardiac puncture and the
lungs were removed from the thoracic cavity and inflated with
pH balanced 4% formaldehyde fixative (pH
 
 
 
7.4). A sagittal block
of the whole left lung was dehydrated and embedded in paraffin
and 5-
 
m
 
m sections were stained with hematoxylin and eosin and
examined by light microscopy. Sections were examined for the
presence of perivascular and peribronchiolar infiltrates by an in-
vestigator blinded to the treatment exposure or genotype groups.
 
Statistical Analysis.
 
Computations were performed with the
JMP
 
®
 
 3.1.5 (SAS Institute Inc.) statistical package. A Tukey-
Kramer HSD multiple comparison test was used to assess differ-
ences among the four treatment groups. For nonparametric data,
differences between groups were analyzed using the Wilcoxon
rank sum test. When appropriate, results are expressed as means 
 
6
 
SEM, and unless otherwise stated were considered statistically sig-
nificant at the
 
 P 
 
, 
 
0.05 level.
 
Results
 
Basal Expression of Pulmonary NOS Activity.
 
In naive WT
mice exposed to neither PBS nor OVA, basally expressed
total pulmonary NOS activity was detectable at a low level
(0.45 
 
6
 
 0.08 pmol citrulline/mg/min), of which 75 
 
6
 
 9%
was accounted for by iNOS activity. In WT mice sensi-
tized to OVA, but only challenged with aerosolized PBS,
there was no change in total NOS activity (0.44 
 
6
 
 0.12
pmol citrulline/mg/min, P 5 NS versus naive WT) or
iNOS activity (80 6 12% of total NOS, P 5 NS versus
naive WT) (Fig. 1).
Basally expressed levels of total NOS activity were not
significantly different in NOS3-KO (eNOS knockout),
NOS1-KO (nNOS knockout), NOS1&3-KO (nNOS and
eNOS double knockout), or NOS2-KO (iNOS knockout)
mice in comparison with WT mice (analysis of variance on
ranks, P 5 0.23). The absolute level of cNOS activity (i.e.,
activity that was attributable to eNOS and nNOS) was not
affected in the single cNOS KO strains, NOS1-KO and
NOS3-KO, in comparison with the WT strain, but was
significantly reduced in the double cNOS knockout
(NOS1&3-KO) mice (0.0 6 0.0 versus 0.08 6 0.02 pmol
citrulline/mg/min in naive WT, P , 0.05). The proportion
of total NOS activity characterized as iNOS activity was
not significantly different among WT, NOS1-KO, and
NOS3-KO mice, but was increased in NOS1&3-KO mice
(100 6 0% of total NOS, P , 0.05 versus WT), and was
markedly reduced in NOS2-KO mice to a level not different
from zero (11 6 6% of total NOS, P , 0.01 versus WT).
Effects of Antigen Sensitization and Acute Antigen Exposure
on Pulmonary NOS Activity. Aerosol OVA exposure in
OVA-sensitized (OVA/OVA) WT mice was associated1624 NOS in a Murine Asthma Model
with markedly increased total NOS activity (1.76 6 0.30
pmol citrulline/mg/min, P , 0.01 versus naive WT), due
completely to an increase in iNOS activity (99 6 1% of to-
tal NOS, P , 0.05 versus WT) (Fig. 1). OVA sensitization
and challenge was associated with similar increases in total
NOS activity and iNOS activity in NOS1-KO, NOS3-
KO, and NOS1&3-KO mice. In contrast, OVA sensitiza-
tion and challenge in NOS2-KO mice was not associated
with any increase in total NOS (0.17 6 0.06 versus 0.33 6
0.10 pmol citrulline/mg/min in naive NOS2-KO, P 5
NS) or iNOS activity (0.08 6 0.03 versus 0.04 6 0.02
pmol citrulline/mg/min in naive NOS2-KO, P 5 NS).
Airway Responsiveness in Mice Sensitized with OVA and
Challenged with Either OVA or PBS. Airway responsiveness
was measured in anesthetized OVA/OVA or OVA/PBS-
treated mice. Airway responsiveness, expressed as the
logED200RL, was measured in OVA/OVA NOS2-KO (n 5
7), OVA/OVA WT (SV129/B6, n 5 10), OVA/OVA
NOS3-KO (n 5 12), OVA/OVA NOS1&3-KO (n 5 10),
OVA/OVA NOS1-KO (n 5 11), and OVA/OVA WT (B6,
n 5 15 mice) (Fig. 2, A and B). Analysis of airway reactivity
(assessed by the logED200RL) revealed no significant differ-
ences between the OVA/OVA NOS2-KO and OVA/OVA
WT (on a B6 background) groups (P 5 0.31, Fig. 2 B).
There was a significant induction in allergen-induced airway
hyperresponsiveness for both the NOS2-KO and WT (B6)
groups when compared with their respective OVA/PBS
control groups (P , 0.05). The OVA/PBS NOS2-KO
group was significantly less responsive than the OVA/PBS
WT (B6) group (P , 0.001, data not shown). When the
methacholine-induced airway responses were analyzed in the
OVA/OVA NOS1-KO and OVA/OVA NOS1&3-KO
groups, there were no significant differences between the
two groups (P 5 0.76). When the OVA/OVA NOS1-KO
airway responses were compared with the OVA/OVA
NOS3-KO mice, the OVA/OVA NOS1-KO mice were sig-
nificantly less responsive to methacholine challenge (P  5
0.0062). Similarly, when the OVA/OVA NOS1&3-KO air-
way responses were compared with the OVA/OVA NOS3-
KO mice, the OVA/OVA NOS1&3-KO mice were signifi-
cantly less responsive to methacholine challenge (P 5 0.016).
Therefore, the OVA/OVA NOS1&3-KO and OVA/OVA
NOS1-KO groups were the most hyporesponsive of the
OVA/OVA groups, whereas the OVA/OVA WT (B6 or
SV129/B6) and OVA/OVA NOS2-KO groups were the
most responsive (Fig. 2, A and B). There were no significant
differences between the OVA/PBS control groups (on a B6
or SV129/B6 background) with the single exception that the
OVA/PBS NOS1&3-KO group was significantly less re-
sponsive to methacholine challenge when compared with the
OVA/PBS WT (SV129/B6) group (P 5 0.004) (data not
shown). Inducible NOS (iNOS) is upregulated in cases of
human allergic asthma (18, 28) and is believed to represent
the main source of increased expired NO, a molecule be-
lieved to modulate airway function (50). The lack of a differ-
ence between the OVA/OVA NOS2-KO and OVA/OVA
WT (B6) groups was unexpected and prompted us to carry
out a second set of experiments to confirm these results using
a different methodology for measuring airway obstruction
and a modified sensitization and challenge protocol. As there
were no discernible differences in airway reactivity after 7 d
of daily allergen exposures, we reasoned that a shorter more
acute exposure may reveal a difference in airway responsive-
ness between the OVA/OVA NOS2-KO and OVA/OVA
WT groups. In this second set of experiments, Penh, an index
of bronchoconstriction, was measured using a whole body
plethysmograph system in awake OVA/OVA NOS2-KO
(n 5 14) and OVA/OVA WT (n 5 13) mice. Analysis of
aerosol methacholine dose–response curves similarly revealed
no significant differences in the degree of airway responsive-
ness between the OVA/OVA NOS2-KO and OVA/OVA
WT groups, confirming the earlier data obtained by measur-
ing RL (Fig. 3). These results indicate that our observation of
no difference in airway responsiveness between WT and
NOS2-KO mice is not an artifact of our specific protocols.
Figure 1. Assessment of calcium-dependent (cNOS, eNOS, and
nNOS activity) and calcium-independent (iNOS activity) pulmonary
NOS activity in OVA/PBS and OVA/OVA WT and NOS-deficient
mice. Calcium-dependent (top) and -independent (bottom) NOS activity
was measured in whole lung preparations as described in Materials and
Methods. Data represents means 6 SEM. #P  , 0.05 compared with
OVA/PBS, same genotype. ¶P , 0.05 compared with WT, same treat-
ment. Black bars, OVA/OVA; hatched bars, OVA/PBS.1625 De Sanctis et al.
Effects of Antigen Sensitization and Acute Antigen Exposure
on BAL Total Cell Counts and Differentials. Aerosol OVA
exposure in all OVA-sensitized mice was associated with a
significant increase in total cell counts in BAL fluid com-
pared with OVA-sensitized and PBS-challenged mice. The
BAL total cell counts did not differ among the WT,
NOS2-KO, NOS1-KO, NOS3-KO, and NOS1&3-KO
OVA/PBS control groups (data not shown). The BAL total
cell counts (3 103 cells 6 SEM) for the WT (SV129/B6)
(n 5 10), NOS2-KO (n 5 7), NOS1-KO (n 5 11), NOS3-
KO (n 5 16), and NOS1&3-KO (n 5 9) OVA/OVA
groups were 642 6 99.7, 843 6 125, 904 6 149, 883 6
104, 531 6 228 3 103 cells, respectively. There were no
significant differences in the BAL total cell counts among
the OVA-sensitized and -challenged mice groups. There were
no significant differences in the proportions of macrophages,
neutrophils, lymphocytes, and eosinophils in the OVA/OVA
exposed mice among the treatment groups (Table I). Differen-
tial cell counts in the OVA/PBS groups revealed no significant
differences in the proportion of macrophages, neutrophils,
lymphocytes, and eosinophils (Table I).
Effects of Antigen Sensitization and Acute Antigen Exposure on
OVA Specific IgE Levels. Antigen sensitization and challenge
induced a significant increase in serum levels of OVA-speci-
fic IgE in the WT, NOS2-KO, NOS1-KO, NOS3-KO,
and NOS1&3-KO groups compared with OVA-sensitized
and PBS-challenged groups. OVA-specific IgE levels re-
ported as absorbance values (OD 405 nm) measured in the
OVA/OVA WT, NOS2-KO, NOS1-KO, NOS3-KO,
and NOS1&3-KO groups were 0.71 6 0.10, 0.61 6 0.14,
0.43 6 0.16, 0.93 6 0.25, and 0.79 6 0.32, respectively.
There were no significant differences among the OVA/
OVA groups. The values for the absorbance (OD 405 nm)
measured in the OVA/PBS WT, NOS2-KO, NOS1-KO,
NOS3-KO, and NOS1&3-KO groups were 0.03 6 0.01,
0.14 6 0.05, 0.05 6 0.03, 0.11 6 0.06, and 0.03 6 0.03, re-
spectively. Similarly, there were no significant differences
among the OVA/PBS control groups. When the OVA/OVA
groups were compared with their matched OVA/PBS control
groups, there were significant within genotype differences at-
tributable to sensitization (P , 0.05) for all groups with the
exception of the NOS1-KO group, which approached but
did not achieve statistical significance (P 5 0.052).
Effects of Antigen Sensitization and Acute Antigen Exposure
on BAL EPO and Total Protein Levels. BAL EPO and total
protein levels were evaluated as fluid phase indicators of the
Figure 2. (A) Airway responsiveness
measured as ED200RL in anesthetized
OVA/OVA WT (SV129/B6) and NOS1-,
NOS3-, and NOS1&3-deficient mice
(bred on a SV129/B6 background). Air-
way responses were measured from the
methacholine dose–response curves. The
dose necessary to cause a doubling of lung
resistance was calculated by log linear in-
terpolation. (B) Airway responses mea-
sured in anesthetized OVA/OVA WT
(B6) and OVA/OVA NOS2-deficient
mice bred on a C57BL/6 (B6) back-
ground. The log ED200RL values represent
an index of airway responsiveness. There
were no significant differences between
the OVA/OVA WT (B6) and OVA/
OVA NOS2-deficient mice. Numeri-
cally lower values are indicative of in-
creased airway responsiveness. Data repre-
sents mean log ED200RL values 6 SEM.
Figure 3. Airway responsiveness measured by whole body plethysmog-
raphy in awake WT (B6) and NOS2-KO mice. Penh, an index of airway
obstruction, was calculated from the box pressure/time wave form after
aerosolization of increasing doses of methacholine. Numerically higher
values of Penh are indicative of increased airway obstruction. Dose–
response curves are shown for OVA- and PBS-challenged WT and
NOS2-KO mice. Data represents mean Penh values 6 SEM.1626 NOS in a Murine Asthma Model
inflammatory response to allergen challenge. There were no
significant differences in either EPO or total protein levels
within the OVA/OVA or OVA/PBS groups (data not
shown).
Histology Findings. Examination of fixed lung tissue
from the OVA-sensitized and -challenged groups revealed
peribronchial and perivascular accumulation of eosinophils,
granulocytes, and mononuclear cells. No differences in the
degree of airway inflammation or presence of inflammatory
infiltrates were noted between the OVA/OVA WT and
NOS-deficient mice (all NOS KOs). Similarly, the histo-
logical findings in the OVA-sensitized and PBS-challenged
groups were unremarkable with no observable differences
between the KO and WT mice.
Discussion
Systemic sensitization and aerosol challenge with aller-
gen in mice reproduces many of the phenotypic features of
human asthma, including increased airway hyperrespon-
siveness, airway inflammation, and increased antigen-spe-
cific IgE. The role of NO in human asthma or animal
models thereof is unclear, as is the relative contribution of
each of the NOS isoforms. NO has been reported to ex-
hibit both beneficial and deleterious effects in asthma. It has
been reported to be a weak bronchodilator (19–21); how-
ever, others have reported no effect on airway tone (22–
24). Still others have reported that the formation of NO
may have deleterious effects due to its reported cytotoxic
effects (18), and finally it has been reported that NO may
serve as a marker of inflammation (16, 17, 51).
To determine the specific contribution of each of the
NOS isoforms in asthma, we studied mice with targeted
deletions of the endothelial, neuronal, inducible, and dou-
ble endothelial and neuronal NOS isoforms using an estab-
lished model of allergic asthma in the mouse (7, 52). The
use of gene KO mice is advantageous in isolating the spe-
cific contribution of each NOS isoform. Indeed, the use of
NOS inhibitors to dissect out the role of constitutive and
inducible NOS is subject to problems of inhibitor specific-
ity and pharmacokinetic concerns.
Because iNOS has been shown to be upregulated in
asthma and is believed to represent the major source of NO
in the lung (13, 53, 54), we reasoned that iNOS would
play a pivotal role in either relaxing or exacerbating the
allergen induced airway hyperresponsiveness. Airway
responsiveness is classically assessed by analyzing dose–
response relationships in which a bronchoconstrictor is
administered in increasing doses while monitoring the ef-
fects of the agonist on mechanical indices of pulmonary
Table I. Differential Cell Counts Obtained on BAL Fluid from iNOS, nNOS, eNOS, and Double Neuronal and Endothelial KO Mice and 
WT (SV129/B6) Mice Treatment Groups
Genotype Treatment n
Differential cell counts (mean 6 SEM)
Macrophages Neutrophils Lymphocytes Eosinophils
%
NOS2-KO OVA/OVA 6 15.2 6 1.9 5.2 6 1.6 8.7 6 1.4 70.8 6 3.4
NOS2-KO OVA/PBS 5 98.2 6 0.7 0.6 6 0.4 1.2 6 0.6 0.0 6 0.0
P 5 * 0.008 0.02 0.008 0.006
WT OVA/OVA 7 16.3 6 1.8 4.4 6 1.0 5.1 6 0.9 74.1 6 2.1
WT OVA/PBS 5 99.2 6 0.4 0.4 6 0.3 0.4 6 0.3 0.0 6 0.0
P 5 * 0.006 0.005 0.005 0.004
NOS1-KO OVA/OVA 6 15 6 2.3 3.3 6 0.5 4.8 6 0.7 77.0 6 3.1
NOS1-KO OVA/PBS 5 98.2 6 0.6 0.2 6 0.2 1.4 6 0.5 0.2 6 0.2
P 5 * 0.008 0.007 0.016 0.007
NOS3-KO OVA/OVA 6 16.8 6 0.5 3.7 6 0.6 4.8 6 0.8 74.7 6 1.1
NOS3-KO OVA/PBS 5 98.4 6 0.7 0.2 6 0.2 1.0 6 0.3 0.4 6 0.4
P 5 * 0.008 0.007 0.0096 0.007
NOS1,3-KO OVA/OVA 7 19 6 1.2 3.14 6 0.3 5.0 6 0.5 73.6 6 1.5
NOS1,3-KO OVA/PBS 5 98.8 6 0.4 0.2 6 0.2 1.0 6 0.5 0.0 6 0.0
P 5 * 0.005 0.005 0.005 0.004
*P values are for OVA/OVA versus OVA/PBS.1627 De Sanctis et al.
obstruction such as pulmonary resistance (RL) (2, 7, 44,
45). This index of airflow obstruction represents the pres-
sure loss in phase with airflow and is analogous to measures
of pulmonary resistance in human subjects. Our data show
that iNOS is significantly upregulated in the lung tissue of
the WT mice sensitized and challenged with OVA, a find-
ing reported in asthmatics (9, 18). Despite this upregula-
tion, there were no significant differences in airway respon-
siveness, airway inflammation, or cellular recruitment into
the airway space when compared with the NOS2-KO
OVA-challenged treatment group. In this regard our data
do not agree with the recent findings of Xiong et al., who
demonstrated a significant decrease in eosinophilia and sup-
pression of allergic inflammation in NOS2 KO mice im-
munized and challenged with OVA (55). The discrepancy
in their results and our own is likely due to significant dif-
ferences in the immunization and challenge protocols (55).
The immunization and challenge protocol used by Xiong
et al. resulted in z90% eosinophilia in the BAL in their
WT OVA/OVA group, considerably higher than the pro-
portion reported by us and others in models of allergen-
induced airway inflammation in the mouse (7, 52, 56–59).
The lack of a significant difference in the pulmonary
resistance (RL) response to methacholine between the
NOS2-KO OVA/OVA and WT (B6) OVA/OVA mice
prompted us to repeat these experiments using unanesthe-
tized mice studied in a whole body plethysmograph. This
method (47, 60) confirmed our previous observation
whereby the NOS2-KO OVA/OVA and WT OVA/
OVA mice exhibited increased, albeit similar degrees of
airway hyperresponsiveness. In this regard our data are in
agreement with the findings of Xiong et al., who also dem-
onstrated that NOS2-KO mice did not have diminished
airway hyperresponsiveness when compared with WT
mice exposed to an OVA sensitization and challenge pro-
tocol (55). Thus, our data and those of others clearly indi-
cate that allergen-induced airway hyperresponsiveness is
fully expressed in the absence of iNOS.
Analysis of markers of inflammation (total protein and
EPO) in the BAL fluid revealed no significant differences
in our data set between the NOS2-KO and WT OVA/
OVA groups. Additionally, there were no significant differ-
ences in the levels of OVA-specific IgE between any of the
OVA-sensitized and -challenged treatment groups. This is
not surprising given that NO has no reported effects on an-
tigen presentation and processing. These findings indicate
that the iNOS isoform is not important in the genesis of
airway inflammation in this allergic model of asthma.
When airway responsiveness was ascertained in the
NOS3-KO, NOS1-KO, and NOS1&3-KO mice, the
NOS1-KO and NOS1&3-KO OVA/OVA groups exhib-
ited increased airway responsiveness when compared with
their respective controls (OVA/PBS), yet there was signifi-
cantly less enhancement of airway responses secondary to
OVA exposure than  in NOS2-KO and WT mice. The
similar degree of diminished airway hyperresponsiveness
among the NOS1-KO and NOS1&3-KO mice, and the
observation of a more intermediate degree of airway hy-
perresponsiveness in the NOS3-KO OVA/OVA mice, in-
dicate that the nNOS isoform is the one principally respon-
sible for the OVA-induced enhancement of airway
responsiveness. The reduction in allergen-induced airway
hyperresponsiveness in NOS1-KO mice is interesting
given that nNOS has previously been shown to contribute
to baseline airway responsiveness (29). Although the results
of our study do not determine the mechanism(s) by which
nNOS is modulating airway responsiveness, the neuronal-
derived NO may directly effect airway smooth muscle
tone. NO has been implicated in nonadrenergic, noncho-
linergic (NANC)-mediated airway relaxation (30, 31). In-
deed, our data are intriguing given recent studies that have
established linkage of the diagnosis of asthma to a region
that maps near the human nNOS gene (35–37). Aside from
the differences in airway responsiveness, the NOS1-KO
and NOS1&3-KO OVA/OVA groups did not differ in
their degree of airway inflammation, levels of OVA-spe-
cific IgE, or recruitment of inflammatory cells into the
BAL. These findings suggest a noninflammatory link be-
tween the nNOS gene and airway hyperresponsiveness in
this murine model of allergic asthma.
The analysis of lung resistance was performed using software provided by Andrew Jackson (Biomedical En-
gineering at Boston University, Boston, MA). 
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